ArticleScientific reports2026
NETosis activity in patients with glioblastoma multiforme compared to healthy controls.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neutrophil extracellular traps derived from NETosis are present in various clinical conditions characterized by elevated concentrations of circulating DNA (cirDNA), including glioblastoma multiforme (GBM). Therefore, the study was designed to explain whether activated neutrophils are the primary source of cirDNA release into the bloodstream and to explore the associations between the cirDNA fragments and clinicopathological characteristics. Preoperative plasma samples from 50 patients (GBM 65.7 ± 10.5 years) and 80 healthy individuals (HC 70.3 ± 5.2 years) were used to determine the levels of total cirDNA, methylated cirDNA, oxidative cirDNA, and myeloperoxidase (MPO). The GBM patients demonstrated significantly higher cirDNA and MPO compared to HC. In GBM, methylated cfDNA represented 7% of total cirDNA whereas in HC it accounted for 12%. The Kaplan-Meier survival curve analysis showed a higher mortality risk with cirDNA of 958-2540 ng/mL. The ROC analysis indicated the optimal cirDNA threshold of 930 ng/mL for cfDNA (AUC = 0.951, p < 0.001), indicating a very high diagnostic value (sensitivity 88% and specificity 91.2%). Elevated plasma concentrations of total cirDNA and MPO may reflect the intensity of NETosis, with high MPO level supporting the concept that activated neutrophils contribute substantially to the pool of circulating cirDNA pool in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.